Myelofibrosis Curriculum

	Improving Outcomes for Patients with Myelofibrosis: A Case-based Analysis CME, NCPD, CPE John O. Mascarenhas, MD and Sandra Kurtin, PhD, ANP-C, AOCN, FAPO
	Release Date: January 23, 2023 Expiration Date: January 23, 2024
	In this presentation, Dr. Mascarenhas and Dr. Kurtin review a series of case scenarios to demonstrate selecting the most appropriate treatment for specific patient populations from the available options. Additionally, these experts share recommendations for shared decision-making and the importance of patient education. Provided by The University of Texas MD Anderson Cancer Center and MediCom Worldwide, Inc. This activity is supported by educational grants from Bristol Myers Squibb, CTI BioPharma Corp. and Sierra Oncology.
	CE ExpiredView Only, No Credit

	Beyond Ruxolitinib as the Frontline Standard of Care: Current and Emerging Second-Line Therapies CME, NCPD, CPE Prithviraj Bose, MD; and Andrew Kuykendall, MD
	Release Date: December 14, 2022 Expiration Date: December 14, 2023
	In this presentation, Dr. Bose and Dr. Kuykendall discuss available and emerging treatment strategies that may be implemented when patients fail to respond or lose response to ruxolitinib therapy. Additionally, these experts share recommendations and strategies for effectively transitioning from first- to second-line therapy. Provided by The University of Texas MD Anderson Cancer Center and MediCom Worldwide, Inc. This activity is supported by educational grants from Bristol Myers Squibb, CTI BioPharma Corp. and Sierra Oncology.
	CE ExpiredView Only, No Credit

	Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response CME, NCPD, CPE Prithviraj Bose, MD; and John Mascarenhas, MD
	Release Date: November 11, 2022 Expiration Date: November 11, 2023
	In this activity, two experts describe risk factors for disease progression, review methods of assessing for and identifying resistance, and how to manage treatment failure. Provided by The University of Texas MD Anderson Cancer Center and MediCom Worldwide, Inc. This activity is supported by educational grants from Bristol Myers Squibb, CTI BioPharma Corp. and Sierra Oncology.
	CE ExpiredView Only, No Credit